Evidence map›Paper›PMID 36748937›Full record

ArticleArchives of endocrinology and metabolism2023

Screening program for familial hyperchylomicronemia syndrome detection: Experience of a university health system.

Walter Masson, Leandro Barbagelata, Milagros Fleitas, Nicole Herzkovich, Eliana Kerschner, Emiliano Rossi, Daniel Siniawski, María V Ami, Juan P Nogueira

Open access · diamondAbstract read
In one paragraph

Article in Archives of endocrinology and metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Walter MassonServicio de Cardiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, walter.masson@hospitalitaliano.org.ar.
Leandro BarbagelataServicio de Cardiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Milagros FleitasServicio de Cardiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Nicole HerzkovichServicio de Cardiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Eliana KerschnerServicio de Cardiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Emiliano RossiServicio de Cardiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Daniel SiniawskiServicio de Cardiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
María V AmiServicio de Clínica Médica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Juan P NogueiraCentro de Investigación en Endocrinología, Nutrición y Metabolismo (CIENM), Facultad de Ciencias de la Salud, Universidad Nacional de Formosa, Formosa, Argentina.
Hospital Italiano de Buenos Aires · ARNational University of Formosa · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by mutations related to chylomicron metabolism. The objective of this study is to show the development and results of a screening program for FCS in Argentina. Materials and methods: A cross-sectional study was performed. All patients > 18 years with a triglyceride level ≥ 1,000 mg/dL in the period from January 1, 2017 to December 31, 2021 were included. The program was developed in three stages: (1) Review of electronic records and identification of suspected laboratory cases (triglyceride level ≥ 1,000 mg/dL); (2) Identification of suspected clinical cases (all suspected laboratory cases that had no relevant secondary factors) and application of the FCS score to define probable cases (score ≥ 10); (3) Perform genetic tests in probable cases. Results: Globally, 348 suspected laboratory cases (mean age of 49.9 years, 77.3% men) were included. The median triglycerides level was 1,309 mg/dL (interquartile range 1,175-1,607 mg/dL). In total, 231 patients were categorized as suspected clinical cases. After applying the FCS score, 3% of them were classified as "very likely FCS" (probable cases). Four variants of uncertain significance have been identified. No previously reported pathogenic variants were detected. Conclusion: This study shows a screening program for the detection of FCS. Although no patient was diagnosed with FCS, we believe that more programs of these characteristics should be developed in our region, given the importance of early detection of this metabolic disorder.

Indexed as

Hyperlipoproteinemia Type ICross-Sectional StudiesFemaleHumansMaleMiddle AgedTriglyceridesUniversitiesTriglyceridesFamilial hyperchylomicronemia syndromehypertriglyceridemiascreening

Identifiers

PMID36748937
PMCPMC10247249
OpenAlexW4319333637

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.